Medical NewsBiocon gets 2 USFDA observations for Visakhapatnam facility DRRA2 months ago01 mins [ad_1] Biocon gets 2 USFDA observations for Visakhapatnam facility We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link Post navigation Previous: Doctors oppose Punjab govt’s decision to set up medical colleges under PPP modelNext: Are We Ignoring the Long-Term Risks? – Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.
FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease DRRA18 hours ago 0